Available Guidance and Best Practices for Conducting Forced Degradation Studies

Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.

Related Content:

Regulatory/GMP ComplianceQuality SystemsRegulatory Authority ActionsPharmaceutical Technology-02-02-2002

Using Continuous Processes and Automation to Remove Contamination Risk

Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia

FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products